Analytical Data
-
Gene name
APOO
- Application
-
Alternative Names
Apo-O; FAM121B; My025; Family With Sequence Similarity 121B
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BUR5
-
Expression Region
Lys26~Lys198
-
Molecular Weight
24kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APOO (Apolipoprotein O) is a member of the apolipoprotein family, which plays a crucial role in lipid metabolism and cardiovascular health. Research into the recombinant production of APOO protein has gained momentum due to its potential implications in understanding various metabolic disorders. APOO is primarily expressed in the liver and has been associated with the regulation of cholesterol and triglyceride levels, influencing the risk of cardiovascular diseases. Studies suggest that variations in APOO expression levels may contribute to the pathogenesis of conditions such as atherosclerosis and dyslipidemia. Moreover, recent findings indicate that APOO may interact with other key proteins involved in lipid transport and metabolism, further underscoring its significance in the lipid metabolic pathway. Recombinant techniques enable the mass production of APOO protein, facilitating in vitro studies and the exploration of its physiological functions and mechanisms of action. Understanding the structure and function of APOO through recombinant methods can provide insights into its role in health and disease, potentially leading to novel therapeutic approaches for managing lipid-related disorders. As research advances, the characterization of recombinant APOO will aid in elucidating its biological significance and pave the way for future studies aimed at translating these findings into clinical applications.
